HODGKIN LYMPHOMA

This study tests whether a drug called pembrolizumab followed by targeted radiation can cure people with early-stage Hodgkin lymphoma that has returned or not responded to initial treatment. About 22 participants will receive this combination to see if it works well and avoids th…

This study tests whether adding the drug nivolumab to standard chemotherapy (ABVD) can improve the chance of cure for people with high-risk Hodgkin lymphoma. It involves 82 participants with untreated stage III or IV disease. The goal is to see if the combination is safe and help…

This study tests a vaccine designed to protect people who have had a stem cell transplant from a common virus called CMV. The virus can cause serious illness in those with weak immune systems. The vaccine uses a harmless virus to teach the body to fight CMV, aiming to reduce infe…

This study tests a vaccine called Triplex to prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV can cause serious illness in people with weakened immune systems. The vaccine uses harmless pieces of CMV DNA to help the body build immuni…

This early-stage study tests a new drug called IMT-009 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goals are to find a safe dose and learn about side effects. About 67 participants will receive the drug intravenously,…

This study tested a shorter course of chemotherapy (Stanford V) in 88 children and young adults with favorable Hodgkin lymphoma. Those who still had signs of cancer after chemo also received low-dose radiation to the affected area. The goal was to see if this approach could impro…

This study is for children and young adults up to age 21 with high-risk blood cancers like leukemia or lymphoma. It tests a transplant using specially treated donor cells from a family member to reduce the risk of the cancer coming back while lowering the chance of a serious side…

This study tests a combination of two drugs, cobolimab and dostarlimab, in children and young adults (up to age 21) with advanced solid tumors that have not responded to other treatments. The goal is to find the safest dose and see if the drugs can shrink tumors. The study involv…

This study tests a combination of two drugs, nivolumab and axatilimab, in adults with classical Hodgkin lymphoma that has returned or not responded to prior treatments, including anti-PD-1 therapy. The main goal is to see how well the combination shrinks or controls the cancer. N…

This study tests two immunotherapy drugs, ipilimumab and nivolumab, alone or together, in people with classic Hodgkin lymphoma that has returned or not responded to prior treatment. The goal is to shrink or control the cancer. About 13 adults are taking part. The approach aims to…

This study tests a mix of four drugs (brentuximab vedotin, pembrolizumab, doxorubicin, and dacarbazine) in 25 people with untreated Hodgkin lymphoma that is either stage II with a large chest tumor or stage III/IV. The goal is to see if this combination can control the cancer whi…

This study tests a drug called tislelizumab combined with chemotherapy for people whose Hodgkin lymphoma has returned or not responded to initial treatment. The goal is to see if this approach works as well as the standard intensive chemo and stem cell transplant. About 75 adults…

This study tests whether adding the drug pembrolizumab to standard chemotherapy can help children and young adults with Hodgkin lymphoma whose cancer did not shrink enough after initial treatment. About 340 participants will receive the combination therapy. The goal is to see if …

This study tests a new stem cell treatment called MGTA-456 for people with high-risk blood cancers like leukemia and lymphoma. The treatment uses a special process to grow more stem cells from donated umbilical cord blood before transplant. The goal is to help the body rebuild he…

This early-phase study tests whether adding specially treated immune cells (called veto cells) from a donor can help stem cell transplants work better in people with blood cancers like leukemia or lymphoma. The goal is to help the donor cells grow without causing severe graft-ver…

This study aims to see if a treatment plan that works well in the U.S. can also help Chinese children and teens with newly diagnosed Hodgkin lymphoma. About 200 participants aged 1 to 18 will receive a modified version of the COG protocol. Researchers will track how long patients…

This early-phase trial tests whether giving healthy donor NK cells along with two drugs (vactosertib and IL-2) is safe and helps the cells survive longer in people with advanced colorectal, stomach/esophageal, or blood cancers. About 12 participants will receive the combination t…

This study tests whether adding a drug called cyclophosphamide after a stem cell transplant can lower the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The trial includes 35 adults with various blood cancers or sever…

This study tests whether giving different chemotherapy combinations based on a patient's risk level can improve outcomes for children and young adults with Hodgkin lymphoma. About 232 participants will receive one of three treatment plans, with radiation only if needed. The goal …

This study looks at whether a special PET scan using a natural substance called methionine can help doctors see tumors in children and young adults with cancer. About 500 participants will get the scan to check if it can find tumors, tell how aggressive they are, and tell leftove…

This early-phase trial tests whether vaccinating stem cell donors against cytomegalovirus (CMV) can help protect the transplant recipient from CMV infection. About 34 people with blood cancers receiving a donor stem cell transplant will have their donors vaccinated before donatio…

This study tests if shorter courses of radiation are safe for people with lymphoma that has returned or not responded to treatment. About 30 participants will receive different shortened radiation schedules to find the safest dose. The goal is to reduce treatment time while contr…

This study tests a new approach to help childhood cancer survivors who struggle with memory, attention, and thinking after their treatment. Participants use a special light device at home while doing brain-training exercises. The goal is to see if this is practical and if it can …

This study follows 350 stem cell transplant survivors to see how their heart, lungs, and muscles work together over two years. Researchers measure exercise capacity and other health markers to learn why transplant survivors have a higher risk of heart disease. Participants includ…

This study looks at whether a blood test that tracks cancer DNA (called a liquid biopsy) can predict if lymphoma will come back within 1-2 years after initial treatment. Researchers will compare this test to the standard PET scan in 108 adults with B-cell or Hodgkin lymphoma. The…

This study examines how common obstructive sleep apnea (OSA) is in adult survivors of Hodgkin lymphoma who received chest radiation. Researchers will compare 220 survivors to matched healthy controls using sleep tests, brain scans, and neck muscle measurements. The goal is to und…

This study follows over 1,500 young adult survivors of childhood cancers like leukemia, brain tumors, and Hodgkin lymphoma to see how frailty—a measure of physical weakness and vulnerability—changes over five years. Researchers want to find out if frailty can predict future chron…

This study looks back at medical records of 400 elderly patients (age 60+) with Hodgkin lymphoma in China to understand their disease and treatment patterns. Researchers will use this information to create a model that helps doctors predict how the disease will progress and choos…

This study tests a new system that helps doctors better understand the needs of older adults with cancer. The system combines checks on aging, mental health, lifestyle, and social factors. About 35 patients aged 65 and older will try it during their first cancer visit. The goal i…